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1519idarucizumab. The dTT and ECT are sensitive mea-
sures for dabigatran, whereas the aPTT provides an
approximate assessment. All tests showed similar
patterns of reversal, consistent with observations in
healthy volunteers (2).
Peak dabigatran concentration on day 4 was 1,161 
372 ng/ml just before injury. There was a large in-
crease in total plasma dabigatran after idarucizumab
administration (Figure 1B), without increased anti-
coagulation. Total dabigatran includes molecules
bound to idarucizumab or plasma proteins and un-
bound (active) molecules. Idarucizumab remains
predominantly in plasma, and this initiates a shift in
equilibrium of dabigatran molecules from tissues to
the blood compartment where they bind to idaru-
cizumab. The process continues until idarucizumab
becomes saturated with dabigatran or all active dabi-
gatran is bound, as with 120 mg/kg idarucizumab. No
further anticoagulant activity was observed with the
120 mg/kg dose, suggesting that the idarucizumab–
dabigatran complex remains stable and the 2 drugs are
cleared together.
Post-mortem macroscopic evaluation of the heart,
lungs, kidneys, and liver showed no evidence
of thromboembolism. However, limitations of this
study such as the high dabigatran concentrations
and species differences between humans and pigs
must be considered. Clinical trials are warranted to
conﬁrm whether our results are applicable to patients.
This study demonstrates that idarucizumab re-
duces dabigatran-associated bleeding and mortality
in a porcine trauma model. Treatment with idaru-
cizumab stopped bleeding within 15 min and was
associated with an immediate decrease in dabiga-
tran anticoagulant effects. There was no evidence of
safety concerns associated with the administration
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Left Ventricular Size Is
Critical for the
Echocardiographic
Assessment of Chronic
Severe Mitral RegurgitationWe read with great interest the recent paper by
Uretsky et al. (1), who showed that there was only
limited agreement between echocardiographic and
magnetic resonance imaging (MRI) in the assess-
ment of mitral regurgitation (MR). MRI assessment
was more reproducible and more predictive than
echocardiography for left ventricular (LV) reverse
remodeling after mitral surgery. Echocardiographic
evaluation of MR was performed using an integrated
approach based on proximal isovelocity surface area
(PISA), effective regurgitant oriﬁce area, vena con-
tracta, left atrial and LV size, pulmonary vein ﬂow
pattern, and MR Doppler jet characteristics such as
color Doppler area, eccentricity, and temporal varia-
tion. MR volume was calculated using the PISA
method for all patients.
Of 38 patients classiﬁed with severe MR by echo-
cardiography, MRI classiﬁed 12 as severe, yielding
a 32% concordance. On further analysis of data pro-
vided in the manuscript we found that in the subset
of patients with LV end-diastolic diameter (LVEDD)
$55 mm MRI correctly identiﬁed 11 of 19 patients as
FIGURE 1 Inﬂuence of LV Size on MR Concordance and Prediction of MR Concordance on the Basis of LV Size
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(A) Box whisker plot showing the median, ﬁrst/third quartiles, and minimum and maximum value of left ventricular end-diastolic diameter (LVEDD) for
various grades of concordance. (B) Receiver-operating characteristic curve analysis of left ventricular end-diastolic diameter to predict concordance be-
tween echocardiography and magnetic resonance imaging. AUC ¼ area under the curve; CI ¼ conﬁdence interval; LV ¼ left ventricular; MR ¼ mitral
regurgitation; MRI ¼ magnetic resonance imaging; TTE ¼ transthoracic echocardiography.
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1520having severe MR with improved concordance to
58%. LVEDD was signiﬁcantly different in patients
with versus without concordance of MR grade by
echocardiogram and MRI (61  6 mm vs. 52  6 mm;
p < 0.001). Using analysis of variance Tukey test
LVEDD for various subgroup comparisons was:
transthoracic echocardiography (TTE) severe/MRI
severe versus TTE severe/ MRI moderate (61  6 mm
vs. 52  7 mm; p ¼ 0.003); TTE severe/MRI severe
versus TTE severe/MRI mild (61  6 mm vs. 51 6 mm;
p ¼ 0.001); TTE severe/MRI moderate versus TTE
severe/MRI mild (52  7 mm vs. 51  6 mm; p ¼ 0.853)
(Figure 1A). Using receiver-operating characteristic
(ROC) curve analysis the area under curve (AUC) was
0.86 (95% conﬁdence interval [CI]: 0.75 to 0.98;
p < 0.001) for LVEDD to predict concordance between
severe grade by echocardiography and MRI. On the
basis of the ROC analysis the LVEDD cutoff value of
55 mm provided a sensitivity of 83% and speciﬁcity of
77% to predict concordance between echocardiogra-
phy and MRI (Figure 1B). Using logistic regression,
the odds that the MR will be discordant between TTE
and MRI (TTE severe vs. MRI moderate/mild) in-
creases signiﬁcantly with LVEDD <55 mm (odds
ratio: 25; 95% CI: 3 to 226; p ¼ 0.004). Using linear
regression we estimated that the concordance be-
tween TTE and MRI will increase by 0.56 MR grades
for every 10 mm increase in LVEDD (beta ¼ 0.56; 95%
CI 0.26 to 0.86; p < 0.001). Based on our analysis ofthe data, overestimation of MR by echocardiography
is caused by not integrating LV size into the evalua-
tion of MR.
Our analysis of the data and the ﬁndings of
the authors highlight the pitfalls and inherent limi-
tations of current echocardiographic parameters
including PISA/effective regurgitant oriﬁce area to
evaluate MR prior to surgery (2,3). As LVEDD is
reﬂective of chronic remodeling and compensation
from volume overload, we believe the MRI data of
Uretsky et al. support the use of LVEDD as a key
parameter in the echocardiographic assessment of
chronic MR.Asim M. Raﬁque, MD
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Chronic Severe Mitral RegurgitationWe read with interest the letter by Drs. Raﬁque and
Siegel, and thank them for their comments. In our
subpopulation of surgical patients, they show if one
uses the additional criterion of a left ventricular end-
diastolic dimension (LVEDD) $55 mm, concordance
between echocardiography and magnetic resonance
imaging (MRI) improves from 32% to 58%. They
conclude LVEDD should be a key parameter in the
echocardiographic assessment of chronic mitral
regurgitation (MR).
It is well accepted that chronic MR causes an in-
crease in LV size. We previously used this important
relationship to validate the accuracy of MRI for quan-
tifying regurgitant volume (1). We showed a tight
coupling between MR regurgitant volume and LV end-
diastolic volume (r2 ¼ 0.8), but this study was limited
to patients with isolated, primary MR.
Using LV size as an additional criterion may
improve the accuracy of echocardiography in a pop-
ulation of patients, but it is no substitute for the ac-
curate determination of MR severity in an individual
patient. This is because many other common diseases
and conditions affect LV size. Myocardial infarction,
nonischemic cardiomyopathy, and athletic heart can
substantially increase LV size without increasing MR.
Similarly, diseases such as restrictive cardiomyopa-
thy and aortic stenosis can substantially decrease LV
size without decreasing MR. Table 4 shows the limi-
tations of using LVEDD as a criterion for MR severity
(2). For example, patient #29 had an LVEDD of 62 mm,
yet had mild MR, and patient #38 had an LVEDD of
53 mm, yet had severe MR.
Using LV size as a surrogate to avoid overestimation
of MR severity is similar to the strategy advocated by
some, to delay surgery until patients are symptomatic.
The thought being that the presence of symptoms
avoids the possibility of inappropriate surgery in MR
patients that are mistakenly graded as severe (3).
However, as is the case with using any surrogate, a
potential problem is the possibility of confounding
illnesses, especially when they are common. Consider2 relatively common conditions: mild MR and restric-
tive cardiomyopathy. A patient with symptomatic
restrictive cardiomyopathy and mild MR that is
mistakenly graded as severe by echocardiography is at
high risk of undergoing inappropriate surgery.
In summary, we believe echocardiographers should
use all information available to them, including LV
size, to determine MR severity. However, given the
potential inaccuracy of echocardiography, and the cost
and complications of open heart surgery, we are
steadfast in our conclusion that cardiac MRI should be
a strong consideration when important clinical de-
cisions are being made based on MR severity, even in
the presence of symptoms.Seth Uretsky, MD
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Aortic StiffnessComplex Evaluation But Major
Prognostic Signiﬁcance Before TAVRWe read with great interest the paper by Yotti et al.
(1) regarding vascular load and transcatheter aortic
valve replacement (TAVR). This study underlines the
interaction between valvular and vascular functions
in patients with aortic stenosis (AS). The authors
highlighted the increase of vascular load after TAVR,
which limits the afterload relief acutely and may
endanger the cardiovascular prognosis later on.
Although no outcome data were available in this
study, we recently conﬁrmed this prognostic impact
by assessing the signiﬁcance of ascending aortic cal-
ciﬁcations (AAC)—a surrogate of stiffness measured
